Fidarestat

Drugs in R and D

Volumn 3, Issue 4, 2002, Pages 232-234

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOS; ALDOSE REDUCTASE INHIBITOR; AMOA; EPALRESTAT; FIDARESTAT; GLUCOSE; INOSITOL; PLACEBO; SK 860; SORBITOL; STREPTOZOCIN; ZENARESTAT; ALDEHYDE REDUCTASE; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE;

CHINA; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; JAPAN; LD 50; MOTOR NERVE CONDUCTION; NONHUMAN; NOTE; PHARMACODYNAMICS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REGISTRATION; SIDE EFFECT; SOUTH KOREA; TAIWAN; TOXICITY TESTING; UNITED STATES; ANIMAL; CHEMISTRY; REVIEW; STATISTICS;

ALDEHYDE REDUCTASE; ANIMALS; CLINICAL TRIALS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES;

EID: 1842848576     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203040-00002     Document Type: Note

References (8)

1. Mealy N, Castañer J. SNK-860: symptomatic antidiabetic, aldose reductase inhibitor. Drugs of the Future 21: 261-265, Mar 1996
2. Yamaguchi T, Miura K, Usui T, et al. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4,4′-imidazolidine]-2′,5′-diones. Arzneimittel-Forschung/Drug Research 44: 344-348, Mar 1994
3. Mizuno K, Kato N, Matsubara. A, et al. Effects of a new aldose reductase inhibitor, (2S, 4S)-6- fluoro-2′,5′-dioxospiro[chroman-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism - Clinical and Experimental 41: 1081-1086, Oct 1992
4. Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, et al. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro-[chroman-4, 4′,-imidazolidine)-2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. Journal of Diabetes and its Complications 8: 27-32, Jan-Mar 1994
5. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24: 1776-1782, Oct 2001
6. Akita M, Mizuno K, Matsubara A, Nakano K, Kurono M. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model. Acta Medica Okayama 47: 299-304, Oct 1993
7. Mizuno K, Kato N, Makino M, et al. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. Journal of Diabetes and its Complications 13: 141-150, May-Jun 1999
8. Asano T, Saito Y, Kawakami M, Yamada N. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. Journal of Diabetes and its Complications 16: 133-138, Mar-Apr 2002